Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory: Molecular and Translational Medicine
Editat de Alan H. B. Wu, Kiang-Teck J. Yeoen Limba Engleză Paperback – 19 apr 2013
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 762.70 lei 6-8 săpt. | |
Humana Press Inc. – 19 apr 2013 | 762.70 lei 6-8 săpt. | |
Hardback (1) | 1077.08 lei 6-8 săpt. | |
Humana Press Inc. – 17 feb 2011 | 1077.08 lei 6-8 săpt. |
Din seria Molecular and Translational Medicine
- 5% Preț: 522.01 lei
- 5% Preț: 837.21 lei
- 5% Preț: 585.92 lei
- 5% Preț: 520.89 lei
- 5% Preț: 759.29 lei
- 5% Preț: 761.42 lei
- 5% Preț: 1385.23 lei
- 5% Preț: 762.70 lei
- 5% Preț: 1086.24 lei
- 5% Preț: 762.18 lei
- 5% Preț: 1088.72 lei
- 5% Preț: 711.27 lei
- 5% Preț: 903.87 lei
- 5% Preț: 839.73 lei
- 5% Preț: 423.99 lei
- 5% Preț: 783.74 lei
- 5% Preț: 1005.61 lei
- 5% Preț: 564.46 lei
- 5% Preț: 638.72 lei
Preț: 762.70 lei
Preț vechi: 802.84 lei
-5% Nou
Puncte Express: 1144
Preț estimativ în valută:
145.99€ • 153.25$ • 120.60£
145.99€ • 153.25$ • 120.60£
Carte tipărită la comandă
Livrare economică 30 ianuarie-13 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781617797262
ISBN-10: 161779726X
Pagini: 288
Ilustrații: XVI, 272 p.
Dimensiuni: 155 x 235 x 15 mm
Greutate: 0.41 kg
Ediția:2011
Editura: Humana Press Inc.
Colecția Humana
Seria Molecular and Translational Medicine
Locul publicării:Totowa, NJ, United States
ISBN-10: 161779726X
Pagini: 288
Ilustrații: XVI, 272 p.
Dimensiuni: 155 x 235 x 15 mm
Greutate: 0.41 kg
Ediția:2011
Editura: Humana Press Inc.
Colecția Humana
Seria Molecular and Translational Medicine
Locul publicării:Totowa, NJ, United States
Public țintă
Professional/practitionerCuprins
Part 1. Basic concepts
Chapter 1. Issues in Translation of Pharmacogenomics into Clinical Practice.
Kiang-Teck J. Yeo, Nikolina Babic, Alan H.B. Wu
Chapter 2. Molecular Diagnostic Methods in Pharmacogenomics Nikolina Babic*, Loren J. Joseph, Kiang-Teck J. Yeo
Chapter 3. Economics of pharmacogenomic testing in clinical practice
Alan H.B. Wu
Chapter 4. From Personalized Medicine to Personalized Justice: The Promises of Translational Pharmacogenomics in the Justice System
Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.
Part 2. Specific pharmacogenomic targets: Chemotherapeutics
Chapter 5. Irinotecan
R. Stephanie Huang, Federico Innocenti and Mark J. Ratain
Chapter 6. Pharmacogenomics of tamoxifen
Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman
Chapter 7. Thiopurines
Terreia S. Jones, Mary V. Relling
Part 3. Specific pharmacogenomic targets: Cardiovascular drugs
Chapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs
Charles Eby
Chapter 9. Clopidogrel and Salicylates
Janice Y Chyou, Marc S Sabatine
Chapter 10. DNA-Guided Statin Therapy
Gualberto Ruaño, Richard L. Seip, Jorge Duconge
Chapter 11. The statin response gene: Kif6
....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.
Part 4. Drugs that cause delayed hypersensitivity
Chapter 12. Abacavir
Elizabeth J. Phillips, Simon A. Mallal
Chapter 13. Allopurinol
Pei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong Chen
Chapter 14. Carbamazepine and its structurally-related antiepiletics
Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen
Part 5........ Miscellaneous drugs
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.
Part 2. Specific pharmacogenomic targets: Chemotherapeutics
Chapter 5. Irinotecan
R. Stephanie Huang, Federico Innocenti and Mark J. Ratain
Chapter 6. Pharmacogenomics of tamoxifen
Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman
Chapter 7. Thiopurines
Terreia S. Jones, Mary V. Relling
Part 3. Specific pharmacogenomic targets: Cardiovascular drugs
Chapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs
Charles Eby
Chapter 9. Clopidogrel and Salicylates
Janice Y Chyou, Marc S Sabatine
Chapter 10. DNA-Guided Statin Therapy
Gualberto Ruaño, Richard L. Seip, Jorge Duconge
Chapter 11. The statin response gene: Kif6
....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.
Part 4. Drugs that cause delayed hypersensitivity
Chapter12. Abacavir
Elizabeth J. Phillips, Simon A. Mallal
Chapter 13. Allopurinol
Pei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong Chen
Chapter 14. Carbamazepine and its structurally-related antiepiletics
Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen
Part 5........ Miscellaneous drugs
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Chapter 14. Carbamazepine and its structurally-related antiepiletics
Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen
Part 5........ Miscellaneous drugs
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Chapter 1. Issues in Translation of Pharmacogenomics into Clinical Practice.
Kiang-Teck J. Yeo, Nikolina Babic, Alan H.B. Wu
Chapter 2. Molecular Diagnostic Methods in Pharmacogenomics Nikolina Babic*, Loren J. Joseph, Kiang-Teck J. Yeo
Chapter 3. Economics of pharmacogenomic testing in clinical practice
Alan H.B. Wu
Chapter 4. From Personalized Medicine to Personalized Justice: The Promises of Translational Pharmacogenomics in the Justice System
Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.
Part 2. Specific pharmacogenomic targets: Chemotherapeutics
Chapter 5. Irinotecan
R. Stephanie Huang, Federico Innocenti and Mark J. Ratain
Chapter 6. Pharmacogenomics of tamoxifen
Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman
Chapter 7. Thiopurines
Terreia S. Jones, Mary V. Relling
Part 3. Specific pharmacogenomic targets: Cardiovascular drugs
Chapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs
Charles Eby
Chapter 9. Clopidogrel and Salicylates
Janice Y Chyou, Marc S Sabatine
Chapter 10. DNA-Guided Statin Therapy
Gualberto Ruaño, Richard L. Seip, Jorge Duconge
Chapter 11. The statin response gene: Kif6
....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.
Part 4. Drugs that cause delayed hypersensitivity
Chapter 12. Abacavir
Elizabeth J. Phillips, Simon A. Mallal
Chapter 13. Allopurinol
Pei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong Chen
Chapter 14. Carbamazepine and its structurally-related antiepiletics
Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen
Part 5........ Miscellaneous drugs
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.
Part 2. Specific pharmacogenomic targets: Chemotherapeutics
Chapter 5. Irinotecan
R. Stephanie Huang, Federico Innocenti and Mark J. Ratain
Chapter 6. Pharmacogenomics of tamoxifen
Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman
Chapter 7. Thiopurines
Terreia S. Jones, Mary V. Relling
Part 3. Specific pharmacogenomic targets: Cardiovascular drugs
Chapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs
Charles Eby
Chapter 9. Clopidogrel and Salicylates
Janice Y Chyou, Marc S Sabatine
Chapter 10. DNA-Guided Statin Therapy
Gualberto Ruaño, Richard L. Seip, Jorge Duconge
Chapter 11. The statin response gene: Kif6
....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.
Part 4. Drugs that cause delayed hypersensitivity
Chapter12. Abacavir
Elizabeth J. Phillips, Simon A. Mallal
Chapter 13. Allopurinol
Pei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong Chen
Chapter 14. Carbamazepine and its structurally-related antiepiletics
Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen
Part 5........ Miscellaneous drugs
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Chapter 14. Carbamazepine and its structurally-related antiepiletics
Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen
Part 5........ Miscellaneous drugs
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Recenzii
From the reviews:
“The book is written for clinical laboratory directors ‘contemplating or assigned the task of establishing a pharmacogenomics laboratory,’ pharmacologists, and interested clinicians who may have to interpret results. This book also would be of interest to … allied health practitioners, regulators, reimbursers, and test device manufacturers. … The writing is concise, clear, and accessible for what might be considered a complex topic. … Get this book if you want a quick, concise, and fascinating read about the current world and use of pharmacogenomic testing.” (Valerie L. Ng, Doody’s Review Service, May, 2011)
“The book is written for clinical laboratory directors ‘contemplating or assigned the task of establishing a pharmacogenomics laboratory,’ pharmacologists, and interested clinicians who may have to interpret results. This book also would be of interest to … allied health practitioners, regulators, reimbursers, and test device manufacturers. … The writing is concise, clear, and accessible for what might be considered a complex topic. … Get this book if you want a quick, concise, and fascinating read about the current world and use of pharmacogenomic testing.” (Valerie L. Ng, Doody’s Review Service, May, 2011)
Textul de pe ultima copertă
While the basic principles of personalized medicine and pharmacogenomics has been covered by numerous texts, there are none to date that focuses on the specific tests themselves that are in current clinical practice and those that are being proposed for implementation in the near future. Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory focuses almost entirely on the specifics of each test that is needed to implement these tests into a clinical laboratory. This volume presents the first compilation of the tests currently in routine clinical use. The chapter authors of this unique and invaluable title comprise a range of renowned authorities and investigators who have conducted the essential clinical trials necessary to justify pharmacogenomic testing today. The book is divided into four parts: Basic Concepts, Specific Pharmacogenomic Targets, Drugs that Cause Delayed Hypersensitivity, and Miscellaneous Drugs. Each author provides a pharmacologic background on the target drug, the need for pharmacogenomic testing, and how results can be translated into clinical decisions. Where appropriate, case studies are given to illustrate typical clinical scenarios. An extensive bibliography is provided so that the reader can refer to the original studies. This well-designed resource will appeal to clinical laboratory directors who are contemplating or assigned the task of establishing a pharmacogenomics laboratory and a wide range of clinicians who must interpret results of testing. Focused and immensely useful, Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory is a timely and outstanding contribution to the literature and will be instrumental in defining this rapidly growing field.
Caracteristici
First book to focus on specific tests used in current clinical practice Each chapter authored by an expert in the application covered